{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T05:08:47Z","timestamp":1789189727128,"version":"build-2803163510"},"reference-count":102,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["amjmedsci.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The American Journal of the Medical Sciences"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.amjms.2026.07.013","type":"journal-article","created":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T22:58:34Z","timestamp":1785538714000},"page":"316-328","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Diffuse alveolar hemorrhage in ANCA-associated vasculitis: Current evidence and multimodal treatment approaches"],"prefix":"10.1016","volume":"372","author":[{"given":"Chanokporn","family":"Puchongmart","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Varote","family":"Shotelersuk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nithila","family":"Sivakumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tulaton","family":"Sodsri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ben","family":"Thiravetyan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Allan","family":"Bueso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tushi","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenneth","family":"Nugent","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.amjms.2026.07.013_bib0001","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1002\/art.39562","article-title":"Diffuse alveolar hemorrhage secondary to antineutrophil cytoplasmic antibody-associated vasculitis: predictors of Respiratory failure and clinical outcomes","volume":"68","author":"Cartin-Ceba","year":"2016","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.amjms.2026.07.013_bib0002","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaut.2019.102397","article-title":"Alveolar haemorrhage in ANCA-associated vasculitis: long-term outcome and mortality predictors","volume":"108","author":"Quartuccio","year":"2020","journal-title":"J Autoimmun"},{"issue":"9","key":"10.1016\/j.amjms.2026.07.013_bib0003","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1164\/rccm.202308-1426OC","article-title":"Alveolar hemorrhage in antineutrophil cytoplasmic antibody-associated vasculitis: results of an international randomized controlled trial (PEXIVAS)","volume":"209","author":"Fussner","year":"2024","journal-title":"Am J Respir Crit Care Med"},{"issue":"2","key":"10.1016\/j.amjms.2026.07.013_bib0004","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1038\/s41584-018-0145-y","article-title":"Pathogenesis and therapeutic interventions for ANCA-associated vasculitis","volume":"15","author":"Nakazawa","year":"2019","journal-title":"Nat Rev Rheumatol"},{"issue":"4","key":"10.1016\/j.amjms.2026.07.013_bib0005","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1055\/s-0038-1668533","article-title":"Alveolar hemorrhage in vasculitis (Primary and Secondary)","volume":"39","author":"Nasser","year":"2018","journal-title":"Semin Respir Crit Care Med"},{"issue":"8","key":"10.1016\/j.amjms.2026.07.013_bib0006","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.1002\/art.41773","article-title":"American College of Rheumatology\/Vasculitis Foundation Guideline for the management of antineutrophil cytoplasmic antibody-associated Vasculitis","volume":"73","author":"Chung","year":"2021","journal-title":"Arthritis Rheumatol"},{"issue":"3","key":"10.1016\/j.amjms.2026.07.013_bib0007","doi-asserted-by":"crossref","first-page":"S71","DOI":"10.1016\/j.kint.2023.10.008","article-title":"KDIGO 2024 clinical practice guideline for the management of antineutrophil cytoplasmic antibody (ANCA)\u2013Associated vasculitis","volume":"105","author":"Floege","year":"2024","journal-title":"Kidney Int"},{"issue":"4","key":"10.1016\/j.amjms.2026.07.013_bib0008","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1016\/j.iac.2012.08.001","article-title":"Update on diffuse alveolar hemorrhage and pulmonary vasculitis","volume":"32","author":"Krause","year":"2012","journal-title":"Immunol Allergy Clin North Am"},{"issue":"3","key":"10.1016\/j.amjms.2026.07.013_bib0009","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2023-003082","article-title":"Systematic literature review informing the 2022 update of the EULAR recommendations for the management of ANCA-associated vasculitis (AAV): part 1-treatment of granulomatosis with polyangiitis and microscopic polyangiitis","volume":"9","author":"Schirmer","year":"2023","journal-title":"RMD Open"},{"issue":"1","key":"10.1016\/j.amjms.2026.07.013_bib0010","doi-asserted-by":"crossref","first-page":"5","DOI":"10.2169\/internalmedicine.52.8863","article-title":"Diffuse alveolar haemorrhage in ANCA-associated vasculitis","volume":"52","author":"West","year":"2013","journal-title":"Intern Med"},{"issue":"7","key":"10.1016\/j.amjms.2026.07.013_bib0011","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1056\/NEJMoa1803537","article-title":"Plasma exchange and glucocorticoids in severe ANCA-associated vasculitis","volume":"382","author":"Walsh","year":"2020","journal-title":"N Engl J Med"},{"issue":"38","key":"10.1016\/j.amjms.2026.07.013_bib0012","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3310\/PNXB5040","article-title":"Plasma exchange and glucocorticoids to delay death or end-stage renal disease in anti-neutrophil cytoplasm antibody-associated vasculitis: PEXIVAS non-inferiority factorial RCT","volume":"26","author":"Jayne","year":"2022","journal-title":"Health Technol Assess"},{"issue":"19","key":"10.1016\/j.amjms.2026.07.013_bib0013","doi-asserted-by":"crossref","first-page":"5688","DOI":"10.3390\/jcm13195688","article-title":"Critically ill patients with newly diagnosed anti-neutrophil cytoplasmic antibody-associated vasculitis: case series and literature review","volume":"13","author":"Rukavina","year":"2024","journal-title":"J Clin Med"},{"issue":"4","key":"10.1016\/j.amjms.2026.07.013_bib0014","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1097\/PAP.0000000000000154","article-title":"Pathophysiology of ANCA-associated vasculitis","volume":"24","author":"Al-Hussain","year":"2017","journal-title":"Adv Anat Pathol"},{"issue":"1","key":"10.1016\/j.amjms.2026.07.013_bib0015","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1136\/ard-2022-223764","article-title":"EULAR recommendations for the management of ANCA-associated vasculitis: 2022 update","volume":"83","author":"Hellmich","year":"2024","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"10.1016\/j.amjms.2026.07.013_bib0016","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1056\/NEJMoa0909905","article-title":"Rituximab versus cyclophosphamide for ANCA-associated vasculitis","volume":"363","author":"Stone","year":"2010","journal-title":"N Engl J Med"},{"issue":"7","key":"10.1016\/j.amjms.2026.07.013_bib0017","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1056\/NEJMoa2023386","article-title":"Avacopan for the treatment of ANCA-associated vasculitis","volume":"384","author":"Jayne","year":"2021","journal-title":"N Engl J Med"},{"issue":"3S","key":"10.1016\/j.amjms.2026.07.013_bib0018","first-page":"S71","article-title":"KDIGO 2024 clinical practice guideline for the management of antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis","volume":"105","year":"2024","journal-title":"Kidney Int"},{"issue":"2","key":"10.1016\/j.amjms.2026.07.013_bib0019","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1053\/j.ajkd.2023.02.003","article-title":"KDOQI US commentary on the 2021 KDIGO clinical Practice Guideline for the management of glomerular diseases","volume":"82","author":"Beck","year":"2023","journal-title":"Am J Kidney Dis"},{"issue":"1","key":"10.1016\/j.amjms.2026.07.013_bib0020","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1186\/s12882-019-1226-0","article-title":"Intravenous pulse methylprednisolone for induction of remission in severe ANCA associated vasculitis: a multi-center retrospective cohort study","volume":"20","author":"Chanouzas","year":"2019","journal-title":"BMC Nephrol"},{"issue":"7","key":"10.1016\/j.amjms.2026.07.013_bib0021","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1056\/NEJMoa1803537","article-title":"Plasma exchange and glucocorticoids in severe ANCA-associated vasculitis","volume":"382","author":"Walsh","year":"2020","journal-title":"N Engl J Med"},{"issue":"4s","key":"10.1016\/j.amjms.2026.07.013_bib0022","first-page":"S1","article-title":"2021 Clinical practice guideline for the management of glomerular diseases","volume":"100","year":"2021","journal-title":"Kidney Int"},{"issue":"Suppl 3","key":"10.1016\/j.amjms.2026.07.013_bib0023","doi-asserted-by":"crossref","first-page":"iii68","DOI":"10.1093\/rheumatology\/kez605","article-title":"B-cell treatment in ANCA-associated vasculitis","volume":"59","author":"Karras","year":"2020","journal-title":"Rheumatol"},{"issue":"3","key":"10.1016\/j.amjms.2026.07.013_bib0024","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1056\/NEJMoa0909905","article-title":"Rituximab versus cyclophosphamide for ANCA-associated vasculitis","volume":"363","author":"Stone","year":"2010","journal-title":"N Engl J Med"},{"issue":"10","key":"10.1016\/j.amjms.2026.07.013_bib0025","doi-asserted-by":"crossref","first-page":"3077","DOI":"10.1093\/ndt\/gfr507","article-title":"Rituximab in ANCA-associated vasculitis: a revolution?","volume":"26","author":"Cohen Tervaert","year":"2011","journal-title":"Nephrol Dial Transplant"},{"issue":"3","key":"10.1016\/j.amjms.2026.07.013_bib0026","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1093\/rheumatology\/ket381","article-title":"Rituximab for induction and maintenance treatment of ANCA-associated vasculitides: a multicentre retrospective study on 80 patients","volume":"53","author":"Charles","year":"2014","journal-title":"Rheumatology"},{"issue":"4","key":"10.1016\/j.amjms.2026.07.013_bib0027","doi-asserted-by":"crossref","first-page":"e134","DOI":"10.1378\/chest.14-1884","article-title":"Isolated pauciimmune pulmonary capillaritis successfully treated with rituximab","volume":"147","author":"Thompson","year":"2015","journal-title":"Chest"},{"issue":"7","key":"10.1016\/j.amjms.2026.07.013_bib0028","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1136\/ard-2022-223559","article-title":"Rituximab versus azathioprine for maintenance of remission for patients with ANCA-associated vasculitis and relapsing disease: an international randomised controlled trial","volume":"82","author":"Smith","year":"2023","journal-title":"Ann Rheum Dis"},{"issue":"7","key":"10.1016\/j.amjms.2026.07.013_bib0029","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1136\/ard-2022-223559","article-title":"Rituximab versus azathioprine for maintenance of remission for patients with ANCA-associated vasculitis and relapsing disease: an international randomised controlled trial","volume":"82","author":"Smith","year":"2023","journal-title":"Ann Rheum Dis"},{"issue":"19","key":"10.1016\/j.amjms.2026.07.013_bib0030","doi-asserted-by":"crossref","first-page":"1771","DOI":"10.1056\/NEJMoa1404231","article-title":"Rituximab versus azathioprine for maintenance in ANCA-associated vasculitis","volume":"371","author":"Guillevin","year":"2014","journal-title":"N Engl J Med"},{"issue":"11","key":"10.1016\/j.amjms.2026.07.013_bib0031","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2022.43799","article-title":"Rituximab vs cyclophosphamide induction therapy for patients with granulomatosis with polyangiitis","volume":"5","author":"Pu\u00e9chal","year":"2022","journal-title":"JAMA Netw Open"},{"issue":"5","key":"10.1016\/j.amjms.2026.07.013_bib0032","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1111\/joim.70024","article-title":"Long-term efficacy of rituximab versus intravenous cyclophosphamide for severe ANCA-associated vasculitis in multicenter REVEAL cohort study","volume":"298","author":"Matsuda","year":"2025","journal-title":"J Intern Med"},{"issue":"6","key":"10.1016\/j.amjms.2026.07.013_bib0033","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1001\/jama.298.6.655","article-title":"Treatment of antineutrophil cytoplasmic antibody associated vasculitis: a systematic review","volume":"298","author":"Bosch","year":"2007","journal-title":"JAMA"},{"issue":"Suppl 1","key":"10.1016\/j.amjms.2026.07.013_bib0034","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1111\/j.1365-2249.2011.04364.x","article-title":"Cyclophosphamide as induction therapy for Wegener\u2019s granulomatosis and microscopic polyangiitis","volume":"164","author":"Langford","year":"2011","journal-title":"Clin Exp Immunol"},{"issue":"12","key":"10.1016\/j.amjms.2026.07.013_bib0035","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1177\/10600280231161592","article-title":"Avacopan for the treatment of anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis","volume":"57","author":"Alihosseini","year":"2023","journal-title":"Ann Pharmacother"},{"issue":"9","key":"10.1016\/j.amjms.2026.07.013_bib0036","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1093\/ndt\/gfae020","article-title":"Avacopan for ANCA-associated vasculitis with hypoxic pulmonary haemorrhage","volume":"39","author":"Chalkia","year":"2024","journal-title":"Nephrol Dial Transpl"},{"issue":"10","key":"10.1016\/j.amjms.2026.07.013_bib0037","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1002\/acr2.11726","article-title":"Treatment of antineutrophil cytoplasmic antibody-associated vasculitis with diffuse alveolar hemorrhage with Avacopan","volume":"6","author":"Falde","year":"2024","journal-title":"ACR Open Rheumatol"},{"issue":"8","key":"10.1016\/j.amjms.2026.07.013_bib0038","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1007\/s40261-023-01298-z","article-title":"Avacopan, a novel competitive C5a receptor antagonist, for severe antineutrophil cytoplasmic autoantibody-associated vasculitis","volume":"43","author":"Nguyen","year":"2023","journal-title":"Clin Drug Investig"},{"issue":"2","key":"10.1016\/j.amjms.2026.07.013_bib0039","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1093\/ndt\/gfaa311","article-title":"Plasma exchange in ANCA-associated vasculitis: the pro position","volume":"36","author":"Kronbichler","year":"2021","journal-title":"Nephrol Dial Transpl"},{"issue":"21","key":"10.1016\/j.amjms.2026.07.013_bib0040","doi-asserted-by":"crossref","first-page":"5154","DOI":"10.3390\/jcm10215154","article-title":"Plasma exchange in ANCA-associated vasculitis: a narrative review","volume":"10","author":"Tsiakas","year":"2021","journal-title":"J Clin Med"},{"issue":"7","key":"10.1016\/j.amjms.2026.07.013_bib0041","doi-asserted-by":"crossref","first-page":"2180","DOI":"10.1681\/ASN.2007010090","article-title":"Randomized trial of plasma exchange or high-dosage methylprednisolone as adjunctive therapy for severe renal vasculitis","volume":"18","author":"Jayne","year":"2007","journal-title":"J Am Soc Nephrol"},{"issue":"2","key":"10.1016\/j.amjms.2026.07.013_bib0042","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1038\/ki.2013.131","article-title":"Long-term follow-up of patients with severe ANCA-associated vasculitis comparing plasma exchange to intravenous methylprednisolone treatment is unclear","volume":"84","author":"Walsh","year":"2013","journal-title":"Kidney Int"},{"key":"10.1016\/j.amjms.2026.07.013_bib0043","doi-asserted-by":"crossref","DOI":"10.1136\/bmj-2021-064604","article-title":"The effects of plasma exchange in patients with ANCA-associated vasculitis: an updated systematic review and meta-analysis","volume":"376","author":"Walsh","year":"2022","journal-title":"BMJ"},{"issue":"3s","key":"10.1016\/j.amjms.2026.07.013_bib0044","first-page":"S71","article-title":"Clinical practice guideline for the management of antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis","volume":"105","year":"2024","journal-title":"Kidney Int"},{"issue":"1","key":"10.1016\/j.amjms.2026.07.013_bib0045","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1186\/s12890-020-01181-z","article-title":"Clinical implication of plasma exchange on life-threatening antineutrophil cytoplasmic antibody-associated vasculitis","volume":"20","author":"Park","year":"2020","journal-title":"BMC Pulm Med"},{"issue":"3","key":"10.1016\/j.amjms.2026.07.013_bib0046","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1097\/SHK.0000000000001389","article-title":"The use of tranexamic acid (TXA) for the management of hemorrhage in trauma patients in the prehospital environment: literature review and descriptive analysis of principal themes","volume":"53","author":"Stansfield","year":"2020","journal-title":"Shock"},{"issue":"2","key":"10.1016\/j.amjms.2026.07.013_bib0047","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1007\/s00228-024-03784-5","article-title":"Advances in the study of nebulized tranexamic acid for pulmonary hemorrhage","volume":"81","author":"Zhang","year":"2025","journal-title":"Eur J Clin Pharmacol"},{"issue":"6","key":"10.1016\/j.amjms.2026.07.013_bib0048","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1016\/j.chest.2018.09.026","article-title":"Inhaled tranexamic acid for hemoptysis treatment: a randomized controlled trial","volume":"154","author":"Wand","year":"2018","journal-title":"Chest"},{"issue":"5","key":"10.1016\/j.amjms.2026.07.013_bib0049","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.1016\/j.chest.2022.11.021","article-title":"Nebulized vs IV tranexamic acid for hemoptysis: a pilot randomized controlled trial","volume":"163","author":"Gopinath","year":"2023","journal-title":"Chest"},{"issue":"4","key":"10.1016\/j.amjms.2026.07.013_bib0050","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1055\/s-2001-16890","article-title":"Recombinant activated factor VII (rFVIIa): characterization, manufacturing, and clinical development","volume":"27","author":"Jurlander","year":"2001","journal-title":"Semin Thromb Hemost"},{"issue":"6","key":"10.1016\/j.amjms.2026.07.013_bib0051","first-page":"37","article-title":"Local pulmonary administration of factor VIIa (rFVIIa) in diffuse alveolar hemorrhage (DAH) - a review of a new treatment paradigm","volume":"2012","author":"Heslet","year":"2012","journal-title":"Biologics"},{"issue":"6","key":"10.1016\/j.amjms.2026.07.013_bib0052","doi-asserted-by":"crossref","DOI":"10.1186\/cc5132","article-title":"Successful pulmonary administration of activated recombinant factor VII in diffuse alveolar hemorrhage","volume":"10","author":"Heslet","year":"2006","journal-title":"Crit Care"},{"issue":"1","key":"10.1016\/j.amjms.2026.07.013_bib0053","doi-asserted-by":"crossref","first-page":"e216","DOI":"10.1542\/peds.2014-1782","article-title":"Intrapulmonary recombinant factor VIIa for diffuse alveolar hemorrhage in children","volume":"135","author":"Park","year":"2015","journal-title":"Pediatrics"},{"issue":"2","key":"10.1016\/j.amjms.2026.07.013_bib0054","doi-asserted-by":"crossref","first-page":"793","DOI":"10.3390\/ijms22020793","article-title":"Treatment of diffuse alveolar hemorrhage: controlling inflammation and obtaining rapid and effective hemostasis","volume":"22","author":"Park","year":"2021","journal-title":"Int J Mol Sci"},{"issue":"4","key":"10.1016\/j.amjms.2026.07.013_bib0055","doi-asserted-by":"crossref","DOI":"10.1378\/chest.1388773","article-title":"Intrapulmonary use of activated factor VII in uncontrolled pulmonary hemorrhage: a case report and review of literature","volume":"142","author":"Agarwal","year":"2012","journal-title":"Chest"},{"issue":"6","key":"10.1016\/j.amjms.2026.07.013_bib0056","doi-asserted-by":"crossref","DOI":"10.1186\/cc5132","article-title":"Successful pulmonary administration of activated recombinant factor VII in diffuse alveolar hemorrhage","volume":"10","author":"Heslet","year":"2006","journal-title":"Crit Care"},{"issue":"2","key":"10.1016\/j.amjms.2026.07.013_bib0057","doi-asserted-by":"crossref","first-page":"123","DOI":"10.2478\/jccm-2022-0004","article-title":"Bronchoscopic intrapulmonary recombinant factor VIIa for diffuse alveolar hemorrhage-induced acute Respiratory failure in MPO-ANCA vasculitis: a case report","volume":"8","author":"Smesseim","year":"2022","journal-title":"J Crit Care Med (Targu Mures)"},{"key":"10.1016\/j.amjms.2026.07.013_bib0058","first-page":"37","article-title":"Local pulmonary administration of factor VIIa (rFVIIa) in diffuse alveolar hemorrhage (DAH) - a review of a new treatment paradigm","volume":"6","author":"Heslet","year":"2012","journal-title":"Biologics"},{"issue":"2","key":"10.1016\/j.amjms.2026.07.013_bib0059","doi-asserted-by":"crossref","first-page":"793","DOI":"10.3390\/ijms22020793","article-title":"Treatment of diffuse alveolar hemorrhage: controlling inflammation and obtaining rapid and effective hemostasis","volume":"22","author":"Park","year":"2021","journal-title":"Int J Mol Sci"},{"issue":"3","key":"10.1016\/j.amjms.2026.07.013_bib0060","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1007\/s00296-025-05812-8","article-title":"ANCA-associated vasculitis and the impact of diffuse alveolar hemorrhage in elderly patients: a retrospective cohort study","volume":"45","author":"Schaier","year":"2025","journal-title":"Rheumatol Int"},{"key":"10.1016\/j.amjms.2026.07.013_bib0061","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaut.2019.102397","article-title":"Alveolar haemorrhage in ANCA-associated vasculitis: long-term outcome and mortality predictors","volume":"108","author":"Quartuccio","year":"2020","journal-title":"J Autoimmun"},{"issue":"2","key":"10.1016\/j.amjms.2026.07.013_bib0062","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.02426-2016","article-title":"Official ERS\/ATS clinical practice guidelines: noninvasive ventilation for acute respiratory failure","volume":"50","author":"Rochwerg","year":"2017","journal-title":"Eur Respir J"},{"issue":"10","key":"10.1016\/j.amjms.2026.07.013_bib0063","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1001\/jama.2024.26244","article-title":"High-flow nasal oxygen vs noninvasive ventilation in patients with acute Respiratory failure: the RENOVATE randomized clinical trial","volume":"333","author":"Maia","year":"2025","journal-title":"Jama"},{"issue":"6","key":"10.1016\/j.amjms.2026.07.013_bib0064","doi-asserted-by":"crossref","DOI":"10.1186\/cc13103","article-title":"Non-invasive ventilation for acute hypoxemic respiratory failure: intubation rate and risk factors","volume":"17","author":"Thille","year":"2013","journal-title":"Crit Care"},{"issue":"Suppl 1","key":"10.1016\/j.amjms.2026.07.013_bib0065","first-page":"S61","article-title":"ISCCM guidelines for the use of non-invasive ventilation in acute Respiratory failure in adult ICUs","volume":"24","author":"Chawla","year":"2020","journal-title":"Indian J Crit Care Med"},{"issue":"8","key":"10.1016\/j.amjms.2026.07.013_bib0066","doi-asserted-by":"crossref","first-page":"5139","DOI":"10.21037\/jtd-19-3991","article-title":"Management of life-threatening hemoptysis in the ICU","volume":"13","author":"Charya","year":"2021","journal-title":"J Thorac Dis"},{"issue":"12","key":"10.1016\/j.amjms.2026.07.013_bib0067","doi-asserted-by":"crossref","first-page":"e206","DOI":"10.4187\/respcare.03162","article-title":"Pulmonary thromboembolism and diffuse alveolar hemorrhage in granulomatosis with polyangiitis vasculitis","volume":"59","author":"Moreno-Gonz\u00e1lez","year":"2014","journal-title":"Respir Care"},{"issue":"9","key":"10.1016\/j.amjms.2026.07.013_bib0068","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1164\/rccm.201703-0548ST","article-title":"An official American thoracic society\/European society of intensive care medicine\/society of critical care medicine clinical practice guideline: mechanical ventilation in adult patients with acute respiratory distress syndrome","volume":"195","author":"Fan","year":"2017","journal-title":"Am J Respir Crit Care Med"},{"issue":"7","key":"10.1016\/j.amjms.2026.07.013_bib0069","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1007\/s00134-023-07050-7","article-title":"ESICM guidelines on acute respiratory distress syndrome: definition, phenotyping and respiratory support strategies","volume":"49","author":"Grasselli","year":"2023","journal-title":"Intensive Care Med"},{"issue":"14","key":"10.1016\/j.amjms.2026.07.013_bib0070","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1001\/jama.2017.14171","article-title":"Effect of lung recruitment and titrated positive end-expiratory pressure (PEEP) vs low PEEP on mortality in patients with acute Respiratory distress syndrome: a randomized clinical trial","volume":"318","author":"Cavalcanti","year":"2017","journal-title":"Jama"},{"issue":"1","key":"10.1016\/j.amjms.2026.07.013_bib0071","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1186\/s13613-019-0540-9","article-title":"Formal guidelines: management of acute respiratory distress syndrome","volume":"9","author":"Papazian","year":"2019","journal-title":"Ann Intensive Care"},{"issue":"23","key":"10.1016\/j.amjms.2026.07.013_bib0072","doi-asserted-by":"crossref","first-page":"2159","DOI":"10.1056\/NEJMoa1214103","article-title":"Prone positioning in severe acute respiratory distress syndrome","volume":"368","author":"Gu\u00e9rin","year":"2013","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.amjms.2026.07.013_bib0073","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1007\/s00296-018-4116-z","article-title":"The role of extra-corporeal membrane oxygenation (ECMO) in the treatment of diffuse alveolar haemorrhage secondary to ANCA-associated vasculitis: report of two cases and review of the literature","volume":"39","author":"Delvino","year":"2019","journal-title":"Rheumatol Int"},{"issue":"4","key":"10.1016\/j.amjms.2026.07.013_bib0074","doi-asserted-by":"crossref","first-page":"A2752","DOI":"10.1016\/j.chest.2024.06.1669","article-title":"Diffuse alveolar hemorrhage requiring veno-venous extracorporeal membrane oxygenation in a patient with rheumatoid arthritis and anca-associated vasculitis","volume":"166","author":"Aljbour Almajali","year":"2024","journal-title":"Chest"},{"issue":"2","key":"10.1016\/j.amjms.2026.07.013_bib0075","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/j.jtha.2022.11.014","volume":"21","author":"Helms","year":"2023","journal-title":"J Thromb Haemost"},{"issue":"3","key":"10.1016\/j.amjms.2026.07.013_bib0076","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1007\/s00134-009-1718-7","article-title":"Parenteral use of recombinant activated factor VII during diffuse alveolar hemorrhage secondary to leptospirosis","volume":"36","author":"Tatopoulos","year":"2010","journal-title":"Intensive Care Med"},{"issue":"6","key":"10.1016\/j.amjms.2026.07.013_bib0077","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1136\/ard-2022-223335","article-title":"2022 EULAR recommendations for screening and prophylaxis of chronic and opportunistic infections in adults with autoimmune inflammatory rheumatic diseases","volume":"82","author":"Fragoulis","year":"2023","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"10.1016\/j.amjms.2026.07.013_bib0078","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1136\/annrheumdis-2017-211796","article-title":"Prophylactic effect of trimethoprim-sulfamethoxazole for pneumocystis pneumonia in patients with rheumatic diseases exposed to prolonged high-dose glucocorticoids","volume":"77","author":"Park","year":"2018","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"10.1016\/j.amjms.2026.07.013_bib0079","doi-asserted-by":"crossref","first-page":"91","DOI":"10.3109\/PL00021707","article-title":"Prediction of and prophylaxis against Pneumocystis pneumonia in patients with connective tissue diseases undergoing medium- or high-dose corticosteroid therapy","volume":"15","author":"Ogawa","year":"2005","journal-title":"Mod Rheumatol"},{"issue":"2","key":"10.1016\/j.amjms.2026.07.013_bib0080","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1001\/jama.2023.9844","article-title":"Prophylaxis against pneumocystis jirovecii pneumonia in adults","volume":"330","author":"Zhou","year":"2023","journal-title":"JAMA"},{"issue":"5","key":"10.1016\/j.amjms.2026.07.013_bib0081","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1136\/ard-2022-223401","article-title":"Risk factors for serious infections in ANCA-associated vasculitis","volume":"82","author":"Odler","year":"2023","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"10.1016\/j.amjms.2026.07.013_bib0082","first-page":"152","article-title":"Pneumocystis jirovecii pneumonia prophylaxis in patients with ANCA vasculitis on Rituximab maintenance Therapy","volume":"4","author":"Aqeel","year":"2024","journal-title":"Glomerular Dis"},{"issue":"4","key":"10.1016\/j.amjms.2026.07.013_bib0083","doi-asserted-by":"crossref","first-page":"1560","DOI":"10.1002\/hep.29800","article-title":"Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance","volume":"67","author":"Terrault","year":"2018","journal-title":"Hepatology"},{"issue":"16","key":"10.1016\/j.amjms.2026.07.013_bib0084","doi-asserted-by":"crossref","first-page":"1664","DOI":"10.1001\/jama.2013.281115","article-title":"Increased HBV reactivation risk with ofatumumab or rituximab","volume":"310","author":"Mitka","year":"2013","journal-title":"Jama"},{"issue":"2","key":"10.1016\/j.amjms.2026.07.013_bib0085","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1053\/j.gastro.2024.11.008","article-title":"AGA clinical practice guideline on the prevention and treatment of Hepatitis B virus reactivation in At-risk individuals","volume":"168","author":"Ali","year":"2025","journal-title":"Gastroenterology"},{"issue":"2","key":"10.1016\/j.amjms.2026.07.013_bib0086","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/j.jhep.2017.03.021","article-title":"EASL 2017 clinical practice guidelines on the management of hepatitis B virus infection","volume":"67","author":"Lampertico","year":"2017","journal-title":"J Hepatol"},{"issue":"28","key":"10.1016\/j.amjms.2026.07.013_bib0087","doi-asserted-by":"crossref","DOI":"10.3346\/jkms.2023.38.e216","article-title":"Efficacy of antiviral prophylaxis up to 6 or 12 months from completion of Rituximab in resolved Hepatitis B patients: a multicenter, randomized study","volume":"38","author":"Jang","year":"2023","journal-title":"J Korean Med Sci"},{"issue":"1","key":"10.1016\/j.amjms.2026.07.013_bib0088","doi-asserted-by":"crossref","first-page":"1","DOI":"10.15585\/mmwr.rr6901a1","article-title":"Guidelines for the treatment of latent tuberculosis infection: recommendations from the national tuberculosis controllers association and CDC","volume":"69","author":"Sterling","year":"2020","journal-title":"MMWR Recomm Rep"},{"key":"10.1016\/j.amjms.2026.07.013_bib0089","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1111\/ajt.12006","article-title":"CMV: prevention, diagnosis and therapy","volume":"13","author":"Kotton","year":"2013","journal-title":"Am J Transpl"},{"issue":"12","key":"10.1016\/j.amjms.2026.07.013_bib0090","doi-asserted-by":"crossref","first-page":"1872","DOI":"10.1002\/art.42324","article-title":"2022 American college of rheumatology\/EULAR classification criteria for takayasu arteritis","volume":"74","author":"Grayson","year":"2022","journal-title":"Arthritis Rheumatol"},{"issue":"1","key":"10.1016\/j.amjms.2026.07.013_bib0091","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1136\/annrheumdis-2019-215882","article-title":"2019 update of EULAR recommendations for vaccination in adult patients with autoimmune inflammatory rheumatic diseases","volume":"79","author":"Furer","year":"2020","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"10.1016\/j.amjms.2026.07.013_bib0092","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1002\/art.42386","article-title":"American College of Rheumatology Guideline for vaccinations in patients with rheumatic and musculoskeletal diseases","volume":"75","author":"Bass","year":"2023","journal-title":"Arthritis Rheumatol"},{"issue":"5","key":"10.1016\/j.amjms.2026.07.013_bib0093","doi-asserted-by":"crossref","first-page":"776","DOI":"10.34067\/KID.0006762020","article-title":"Should PLEX be used for severe AKI and\/or pulmonary hemorrhage in ANCA-associated vasculitis (AAV)? PRO","volume":"2","author":"Derebail","year":"2021","journal-title":"Kidney"},{"issue":"5","key":"10.1016\/j.amjms.2026.07.013_bib0094","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1002\/jca.21820","article-title":"Update to the ASFA guidelines on the use of therapeutic apheresis in ANCA-associated vasculitis","volume":"35","author":"Balogun","year":"2020","journal-title":"J Clin Apher"},{"issue":"4","key":"10.1016\/j.amjms.2026.07.013_bib0095","first-page":"757","article-title":"Plasma exchange for severe alveolar hemorrhage in antineutrophil cytoplasmic antibody\u2013associated vasculitis: emulation of a target trial","volume":"212","author":"Sanna","year":"2026","journal-title":"Am J Respir Crit Care Med"},{"issue":"5","key":"10.1016\/j.amjms.2026.07.013_bib0096","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.1016\/j.chest.2022.11.021","article-title":"Nebulized vs IV tranexamic acid for hemoptysis: a pilot randomized controlled trial","volume":"163","author":"Gopinath","year":"2023","journal-title":"Chest"},{"issue":"3","key":"10.1016\/j.amjms.2026.07.013_bib0097","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1097\/LBR.0000000000000286","article-title":"Intrapulmonary recombinant factor VII as an effective treatment for diffuse alveolar hemorrhage: a case series","volume":"23","author":"Baker","year":"2016","journal-title":"J Bronchol Interv Pulmonol"},{"key":"10.1016\/j.amjms.2026.07.013_bib0098","article-title":"Anticoagulant-free venovenous extracorporeal membrane oxygenation for diffuse alveolar hemorrhage with bowel bleeding caused by antineutrophil cytoplasmic antibody-associated vasculitis: a case report","volume":"34","author":"Esumi","year":"2021","journal-title":"Respir Med Case Rep"},{"issue":"3","key":"10.1016\/j.amjms.2026.07.013_bib0099","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1016\/j.chest.2019.10.021","article-title":"Extracorporeal membrane oxygenation for severe ARDS due to immune diffuse alveolar hemorrhage: a retrospective observational study","volume":"157","author":"Seeliger","year":"2020","journal-title":"Chest"},{"key":"10.1016\/j.amjms.2026.07.013_bib0100","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/j.ejpb.2015.04.015","article-title":"Inhalable tranexamic acid for haemoptysis treatment","volume":"93","author":"Haghi","year":"2015","journal-title":"Eur J Pharm Biopharm"},{"issue":"1","key":"10.1016\/j.amjms.2026.07.013_bib0101","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1007\/s00408-024-00780-5","article-title":"Nebulized tranexamic acid in the management of hemoptysis: an integrative review","volume":"203","author":"Ye","year":"2025","journal-title":"Lung"},{"issue":"3","key":"10.1016\/j.amjms.2026.07.013_bib0102","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1007\/s00408-015-9720-z","article-title":"Use of activated factor VII in patients with diffuse alveolar hemorrhage: a 10 years institutional experience","volume":"193","author":"Pathak","year":"2015","journal-title":"Lung"}],"container-title":["The American Journal of the Medical Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002962926003095?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002962926003095?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T04:38:37Z","timestamp":1789187917000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002962926003095"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":102,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["S0002962926003095"],"URL":"https:\/\/doi.org\/10.1016\/j.amjms.2026.07.013","relation":{},"ISSN":["0002-9629"],"issn-type":[{"value":"0002-9629","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Diffuse alveolar hemorrhage in ANCA-associated vasculitis: Current evidence and multimodal treatment approaches","name":"articletitle","label":"Article Title"},{"value":"The American Journal of the Medical Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.amjms.2026.07.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Southern Society for Clinical Investigation. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}